DataMeds AI, Inc MEDS
3.11
(0.39)
(11.14%)
as of 25 Sep
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 1.22 |
P/FCF ratio |
— | 0.00 | 0.00 |
P/Operating CF |
— | (68.61) | (4.51) |
P/B ratio |
— | 26.73 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 2.22 |
EV/EBITDA |
— | 0.00 | 0.00 |
EV/Operating CF |
— | (165.21) | (4.78) |
EV/FCF |
— | (165.21) | (4.42) |
Quick Ratio |
0.12 | 0.13 | 0.04 |
Current Ratio |
0.12 | 0.40 | 0.09 |
Net Debt/EBITDA |
(0.12) | (4.44) | (0.30) |
Debt/Assets |
103.43% | 40.78% | 77.11% |
Debt/Equity |
(0.12) | 3.47 | (1.89) |
Asset Turnover |
— | 0.63 | 0.53 |
Operating CF/Net income |
0.12 | 0.18 | 0.11 |
Capex/Depreciation |
— | (0.34) | (0.06) |
Interest Coverage |
0.00 | 0.00 | 0.00 |
| 0.00% | (357.65%) | 3,545.16% | |
| 0.00% | (23.78%) | (230.71%) | |
ROIC |
0.00% | (13.20%) | (532.81%) |
Return on Tangible Assets |
113.54% | 30.49% | 378.86% |
Average Days of Receivables |
0.00 | 75.42 | 17.79 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 37.50% | 306.61% |
Intangible Assets out of Total Assets |
0.00 | 0.64 | 0.80 |
Share Based Compensation of Revenue |
— | 5.96% | 234.79% |
Graham Net Nets |
— | (0.20) | (1.41) |
Graham Number |
— | 0.00 | 119.18 |
Earnings Yield |
— | (3.81%) | (360.00%) |
Free Cash Flow Yield |
— | (0.68%) | (41.33%) |
Revenue per Share |
0.00 | 19.18 | 16.44 |
Operating CF per Share |
(0.39) | (1.30) | (7.65) |
Capex per Share |
0.00 | (0.40) | (0.62) |
Free Cash Flow per Share |
(0.39) | (1.70) | (8.27) |
Cash per Share |
0.00 | 1.09 | 0.03 |
Shareholders Equity per Share |
(3.24) | 7.13 | (8.77) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(3.24) | 7.13 | (8.77) |
Free Cash Flow |
(0.35) | (1.60) | (11.74) |
Working Capital |
(2.55) | (22.88) | (26.96) |
Capital Expenditures |
— | (0.38) | (0.88) |
Net Current Asset Value |
(2.90) | (35.43) | (40.09) |
EV/EBIT |
— | 0.00 | 0.00 |
Capex to Sales |
— | 0.02 | 0.04 |
Net Profit Margin |
0.00% | (37.82%) | (433.95%) |
Price to Operating Income |
— | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
— | 2.87 | 68.95 |
Cash ROIC |
13.70% | (5.18%) | (100.02%) |
Accounts Receivable Turnover |
— | 8.88 | 9.56 |
Accounts Payable Turnover |
— | 4.44 | 3.30 |
Inventory Turnover |
— | 0.00 | 5.34 |
Average Days of Payables |
0.00 | 141.31 | 143.36 |
Days of Inventory on Hand |
— | 212.35 | 20.10 |
Average Receivables |
— | 2.04 | 2.44 |
Average Payables |
— | 3.69 | 9.01 |
Average Inventory |
— | — | 5.58 |
Average Assets |
— | 28.84 | 43.90 |
Average Common Equity |
— | 1.92 | (2.86) |
Columns are period end dates